Morgan Stanley Issues Positive Forecast for Clorox (NYSE:CLX) Stock Price

Clorox (NYSE:CLX) had its target price increased by investment analysts at Morgan Stanley from $87.00 to $94.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley‘s price objective points to a potential downside of 6.53% from the stock’s current price.

Other analysts have also recently issued research reports about the company. JPMorgan Chase & Co. upped their price objective on Clorox from $83.00 to $86.00 and gave the company an “underweight” rating in a research report on Tuesday. Zacks Research cut Clorox from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 29th. The Goldman Sachs Group reaffirmed a “sell” rating and set a $74.00 price target on shares of Clorox in a research report on Tuesday. Jefferies Financial Group cut shares of Clorox from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $125.00 to $98.00 in a research note on Tuesday, July 28th. Finally, Wells Fargo & Company raised their price objective on shares of Clorox from $85.00 to $90.00 and gave the stock an “equal weight” rating in a report on Tuesday. One investment analyst has rated the stock with a Buy rating, twelve have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $93.79.

Clorox Stock Performance

Clorox stock traded up $6.77 during midday trading on Wednesday, reaching $100.57. 2,272,558 shares of the company traded hands, compared to its average volume of 2,655,193. The company has a debt-to-equity ratio of 15.80, a current ratio of 0.66 and a quick ratio of 0.38. Clorox has a 12 month low of $79.12 and a 12 month high of $128.90. The firm has a market capitalization of $12.16 billion, a price-to-earnings ratio of 18.07, a price-to-earnings-growth ratio of 3.00 and a beta of 0.59. The business has a 50 day moving average of $88.00 and a two-hundred day moving average of $99.83.

Clorox (NYSE:CLX) last announced its earnings results on Monday, November 2nd. The company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.07 by $0.48. The business had revenue of $1.91 billion during the quarter, compared to analyst estimates of $1.88 billion. Clorox had a net margin of 9.41% and a return on equity of 601.88%. The company’s quarterly revenue was up 33.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.85 EPS. As a group, research analysts predict that Clorox will post 5.68 earnings per share for the current year.

Hedge Funds Weigh In On Clorox

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Clorox in the 2nd quarter worth $958,640,000. Bank of America Corp DE purchased a new stake in shares of Clorox during the second quarter worth about $179,780,000. ProShare Advisors LLC grew its position in shares of Clorox by 6.3% during the third quarter. ProShare Advisors LLC now owns 1,737,891 shares of the company’s stock worth $140,787,000 after purchasing an additional 102,732 shares in the last quarter. Royal Bank of Canada grew its position in shares of Clorox by 20.1% during the first quarter. Royal Bank of Canada now owns 1,418,204 shares of the company’s stock worth $146,969,000 after purchasing an additional 237,301 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Clorox during the 2nd quarter valued at approximately $123,154,000. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Key Stories Impacting Clorox

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Clorox reported adjusted EPS of $1.55, above the $1.07 consensus, and revenue of $1.91 billion, topping estimates of $1.88 billion. Higher sales, cost savings and contributions from GOJO supported the results. Clorox Shares Rally After Q1 Earnings Beat
• Positive Sentiment: The company maintained fiscal 2027 guidance of $5.70–$6.00 in adjusted EPS and $7.6–$7.7 billion in revenue, with the EPS range slightly above consensus. Evercore also upgraded its rating to In-Line from Underperform, citing the new CEO’s turnaround experience. Evercore ISI Group upgrades Clorox to in-line
• Neutral Sentiment: Analyst views remain mixed: UBS raised its price target to $96 while keeping a Neutral rating; Barclays maintained a Sell rating. UBS adjusts Clorox price target
• Negative Sentiment: Clorox expects adjusted earnings near the low end of its fiscal-year range as inflation and higher input costs squeeze margins. The acquisition-related increase in debt has also prompted questions about balance-sheet flexibility and dividend sustainability. Clorox earnings outlook and costs

Clorox Company Profile

The Clorox Company, founded in 1913 and headquartered in Oakland, California, is a consumer and professional products company. It began with household bleach and has expanded into a portfolio of brands serving cleaning, household, personal care, food, and professional markets.

Its brands include Clorox disinfecting and cleaning products, Pine-Sol cleaners, Liquid-Plumr drain care, Kingsford charcoal, Fresh Step and Scoop Away cat litter, Hidden Valley dressings and dips, Brita water filtration products, and Burt’s Bees personal care items.